Quick Answer
Wegovy and Ozempic contain the exact same active ingredient — semaglutide — made by the same manufacturer (Novo Nordisk). The real difference is what they're FDA-approved for and their maximum dose. Ozempic is approved for type 2 diabetes (and reducing cardiovascular/kidney risk in people who have it), with a maximum dose of 2.0 mg weekly. Wegovy is approved for chronic weight management, with a higher maximum dose of 2.4 mg weekly (a 7.2 mg "Wegovy HD" dose was also approved in 2026). They are not meant to be used interchangeably or at the same time.
Same Drug, Different Purpose
Both medications work by mimicking GLP-1, a hormone your gut releases after eating. This:
- Increases insulin release when blood sugar is high
- Lowers how much sugar your liver produces
- Slows how quickly food leaves your stomach
- Signals fullness to your brain, reducing appetite
Ozempic was FDA-approved first, in 2017, specifically for type 2 diabetes. Wegovy followed in 2021 at a higher maximum dose, approved specifically for chronic weight management. Because they carry different approved indications, insurance plans often treat coverage for each very differently — even though the drug inside the pen is chemically the same molecule.
Dosing Differences
| Ozempic | Wegovy | |
|---|---|---|
| Approved for | Type 2 diabetes | Chronic weight management |
| Maximum weekly dose | 2.0 mg | 2.4 mg (7.2 mg "HD" version also available) |
| Typical weight loss in trials | ~8–14% (secondary effect) | ~15–18% (primary goal) |
| Form | Weekly injection; oral tablet also available | Weekly injection; oral tablet also available |
Because Wegovy's approved maximum dose is higher, it tends to produce more weight loss on average — but individual results vary widely, and Ozempic still produces meaningful weight loss for many people even though that's not its primary approved use.
Is It Legal to Use Ozempic "Off-Label" for Weight Loss?
Doctors can legally prescribe Ozempic off-label for weight loss, and this happens often — particularly when insurance covers Ozempic for diabetes but not Wegovy for weight loss. That said, off-label use means you're taking a lower maximum dose than what's specifically studied and approved for weight management, and insurance is far less likely to cover it when the prescription isn't for diabetes.
Side Effects
Because they share the same active ingredient, Wegovy and Ozempic have essentially the same side effect profile — see our full Ozempic side effects guide for details. Side effects may be somewhat more pronounced with Wegovy simply because its approved maximum dose is higher.
Cost Comparison
List prices and savings-program pricing change frequently and vary by manufacturer program, pharmacy, and insurance coverage. As a general pattern:
- Both drugs commonly list in the range of roughly $900–$1,400+ per month without insurance or savings programs
- Manufacturer savings programs and telehealth partnerships can significantly reduce cash price for eligible patients
- Insurance coverage often depends heavily on your diagnosis (diabetes vs. obesity) and your specific plan's formulary
Because pricing shifts often, always confirm current pricing directly with the manufacturer's savings program, your pharmacy, or your insurance plan rather than relying on older published figures.
Can You Switch Between Them?
Only under your doctor's guidance. Because the doses aren't directly interchangeable milligram-for-milligram, and because your insurance coverage may depend on which drug and diagnosis is on file, switching between Ozempic and Wegovy isn't something to do without medical supervision.
Bottom Line
If your goal is diabetes management, Ozempic is the FDA-approved option built and studied for that purpose. If your goal is weight management and you meet the clinical criteria, Wegovy is the version specifically approved and dosed for that. Talk to your doctor about which approved indication actually applies to your situation — it affects both your dosing and what your insurance is likely to cover.
[DRAFT STATUS: Ready for pharmacist review. Dosing, approval, and pricing details reflect research current as of the research date and should be reverified against current FDA labeling and manufacturer program pages before publishing, since GLP-1 pricing and dosing options (e.g., new high-dose formulations) continue to evolve quickly.]
